List of Gene Editing/CRISPR Companies in Netherlands - 8

Overview: Cibus is part of the multi-billion-dollar plant seed industry. Cibus leads the new era of high throughput gene editing technology that can develop plant traits precisely at a fraction of the time and cost of conventional breeding. Cibus is not a seed company. We are a technology company that uses gene editing to develop plant traits. Cibus licenses its traits to seed companies for royalties on seeds that use its traits. Cibus’ target market is Productivity Traits” that improve yields, lower input costs such as chemicals and increase the sustainability and profitability of farming. We have a pipeline of six productivity traits including traits for pod shatter reduction, disease resistance and nutrient use efficiency. Cibus' focus is multi-crop traits for the major crops: canola, rice, soybean, wheat, and corn. In other words, traits that can impact global agriculture sustainability at scale. Technology: Gene editing in agriculture is a plant breeding technology. The promise of gene editing in agriculture is the ability to develop plant traits that are indistinguishable from traits developed using conventional breeding but can be developed at a fraction of the time and cost. To many, gene editing represents agriculture’s “analog to digital” technology moment. It is a technology that changes the speed and scale of trait development. Cibus is at the forefront of this technology moment. Our Rapid Trait Development System™ (RTDS®) and Trait Machine™ process represents the first end-to-end semi-automated plant breeding system. Vision: Cibus’ vision is to be a pure play trait developer; a technology company whose business is to develop and license plant traits to seed companies in exchange for royalties. The licensing of plant traits and germplasm with quantifiable benefits and strong intellectual property is an integral part of the seed industry. Our goal is to be a leader in this segment of the seed industry.

Digi.Bio is bridging the digital and biological world through microfluidic automation and AI. We develop programmable microfluidics platforms, integrated with sensor and AI, to make biology easier to engineer.

GenDx is a global leader in molecular diagnostics for matching stem cell transplant patients with donors, and monitor success of transplantation. We combine our renowned software and reagents for high resolution HLA typing by Next Generation Sequencing and Chimerism monitoring, with ex-cellent customer support and education. We work closely with our partners and clients and share knowledge to advance the field of trans-plant typing and monitoring. With a highly educated and motivated team of about 90 people and 40 distributors, we contribute to the quality of life of transplant patients worldwide.

Chicken hatheries normally cull male chicks at an early age since they do not produce eggs. This company has developed technology that prevents hatcheries from having to cull male chicks. They use a proprietary biomarker, high-speed sampling,and mass spectrometry to identify the gender of a chicken before the egg has hatched. Eggs with male chicks can be destroyed, thus ensuring that male chicks do not hatch and will not need to be culled.

Imagine a world where we conquer cancer and genetic diseases. At NTrans Technologies, we solve key challenges in cell and gene therapy: Delivering life-changing therapies to the right cells and tissues. We leverage nature's own mechanisms for cellular uptake to ensure efficient and safe therapeutic delivery. Welcome to the next frontier of medicine. Our proprietary platform is GMP-ready and sets a new standard in cell and gene therapy. We use a non-viral delivery system to harness macropinocytosis - a natural cellular uptake process - for precise and secure delivery of gene-editing technologies. The mission of NTrans Technologies is to become the leading non-viral delivery platform in cell and gene therapy. Please contact us at: info@ntranstechnologies.com

At Oncosence we target cancer by developing senescence inducing and senolytic (senescent cell killing) compounds

Develops the scopeDx ® platform, a technology that uses proprietary Type III CRISPR-Cas nucleases to detect nucleic acid sequences

Shandong Biotech is a fully-integrated biopharmaceutical company, specializing in the research & development, manufacturing and commercialization of therapeutic products.